Clinical Research Trials Archive – Closed Trials

This is our archive of closed clinical trials, which means that they are no longer accepting new participants or have been concluded. Once a research facility has chosen to close the study, it is sorted into the GPS archive by indication. If you are interested in enrolling in a clinical trial, then please browse our list of active clinical studies.

Zip code

Condition


Search Radius:25 Miles
  • 5
  • 10
  • 15
  • 20
  • 25
  • 30
  • 40
  • 50
  • 100
  • 500
  • All

We've found
33,560
archived clinical trials in
Neurology

HT-3951 vs. Placebo in Stroke Rehabilitation
A Phase 2a, Randomized, Double-Blind, Placebo-Controlled 21-Day Treatment Study, Including an fMRI Sub-Study, to Evaluate the Effect of HT-3951 on Upper Extremity Motor Function Following Ischemic Stroke
Status: Enrolling
Updated:  1/30/2018
Clinical Research Facility
mi
from
Dallas, TX
HT-3951 vs. Placebo in Stroke Rehabilitation
A Phase 2a, Randomized, Double-Blind, Placebo-Controlled 21-Day Treatment Study, Including an fMRI Sub-Study, to Evaluate the Effect of HT-3951 on Upper Extremity Motor Function Following Ischemic Stroke
Status: Enrolling
Updated: 1/30/2018
Clinical Research Facility
mi
from
Dallas, TX
Click here to add this to my saved trials
Screening for Memory Studies
Screening for Memory Studies
Status: Enrolling
Updated:  1/31/2018
VA Palo Alto Health Care System
mi
from
Palo Alto, CA
Screening for Memory Studies
Screening for Memory Studies
Status: Enrolling
Updated: 1/31/2018
VA Palo Alto Health Care System
mi
from
Palo Alto, CA
Click here to add this to my saved trials
Safety and Tolerability Study of EG-1962 in Aneurysmal Subarachnoid Hemorrhage
Nimodipine Microparticles to Enhance Recovery While Reducing TOxicity After subarachNoid Hemorrhage: Phase I/IIa Multicenter, Controlled, Randomized, Open Label, Dose Escalation, Safety, Tolerability, and Pharmacokinectic Study Comparing EG-1962 and Nimodipine in Patients With Aneurysmal Subarachnoid Hemorrhage
Status: Enrolling
Updated:  1/31/2018
Barrow Neurological Institute
mi
from
Phoenix, AZ
Safety and Tolerability Study of EG-1962 in Aneurysmal Subarachnoid Hemorrhage
Nimodipine Microparticles to Enhance Recovery While Reducing TOxicity After subarachNoid Hemorrhage: Phase I/IIa Multicenter, Controlled, Randomized, Open Label, Dose Escalation, Safety, Tolerability, and Pharmacokinectic Study Comparing EG-1962 and Nimodipine in Patients With Aneurysmal Subarachnoid Hemorrhage
Status: Enrolling
Updated: 1/31/2018
Barrow Neurological Institute
mi
from
Phoenix, AZ
Click here to add this to my saved trials
Safety and Tolerability Study of EG-1962 in Aneurysmal Subarachnoid Hemorrhage
Nimodipine Microparticles to Enhance Recovery While Reducing TOxicity After subarachNoid Hemorrhage: Phase I/IIa Multicenter, Controlled, Randomized, Open Label, Dose Escalation, Safety, Tolerability, and Pharmacokinectic Study Comparing EG-1962 and Nimodipine in Patients With Aneurysmal Subarachnoid Hemorrhage
Status: Enrolling
Updated:  1/31/2018
Ronald Reagan UCLA Medical Center
mi
from
Los Angeles, CA
Safety and Tolerability Study of EG-1962 in Aneurysmal Subarachnoid Hemorrhage
Nimodipine Microparticles to Enhance Recovery While Reducing TOxicity After subarachNoid Hemorrhage: Phase I/IIa Multicenter, Controlled, Randomized, Open Label, Dose Escalation, Safety, Tolerability, and Pharmacokinectic Study Comparing EG-1962 and Nimodipine in Patients With Aneurysmal Subarachnoid Hemorrhage
Status: Enrolling
Updated: 1/31/2018
Ronald Reagan UCLA Medical Center
mi
from
Los Angeles, CA
Click here to add this to my saved trials
Safety and Tolerability Study of EG-1962 in Aneurysmal Subarachnoid Hemorrhage
Nimodipine Microparticles to Enhance Recovery While Reducing TOxicity After subarachNoid Hemorrhage: Phase I/IIa Multicenter, Controlled, Randomized, Open Label, Dose Escalation, Safety, Tolerability, and Pharmacokinectic Study Comparing EG-1962 and Nimodipine in Patients With Aneurysmal Subarachnoid Hemorrhage
Status: Enrolling
Updated:  1/31/2018
Rush University Medical Center
mi
from
Chicago, IL
Safety and Tolerability Study of EG-1962 in Aneurysmal Subarachnoid Hemorrhage
Nimodipine Microparticles to Enhance Recovery While Reducing TOxicity After subarachNoid Hemorrhage: Phase I/IIa Multicenter, Controlled, Randomized, Open Label, Dose Escalation, Safety, Tolerability, and Pharmacokinectic Study Comparing EG-1962 and Nimodipine in Patients With Aneurysmal Subarachnoid Hemorrhage
Status: Enrolling
Updated: 1/31/2018
Rush University Medical Center
mi
from
Chicago, IL
Click here to add this to my saved trials
Safety and Tolerability Study of EG-1962 in Aneurysmal Subarachnoid Hemorrhage
Nimodipine Microparticles to Enhance Recovery While Reducing TOxicity After subarachNoid Hemorrhage: Phase I/IIa Multicenter, Controlled, Randomized, Open Label, Dose Escalation, Safety, Tolerability, and Pharmacokinectic Study Comparing EG-1962 and Nimodipine in Patients With Aneurysmal Subarachnoid Hemorrhage
Status: Enrolling
Updated:  1/31/2018
University of Maryland Medical Cnter
mi
from
Baltimore, MD
Safety and Tolerability Study of EG-1962 in Aneurysmal Subarachnoid Hemorrhage
Nimodipine Microparticles to Enhance Recovery While Reducing TOxicity After subarachNoid Hemorrhage: Phase I/IIa Multicenter, Controlled, Randomized, Open Label, Dose Escalation, Safety, Tolerability, and Pharmacokinectic Study Comparing EG-1962 and Nimodipine in Patients With Aneurysmal Subarachnoid Hemorrhage
Status: Enrolling
Updated: 1/31/2018
University of Maryland Medical Cnter
mi
from
Baltimore, MD
Click here to add this to my saved trials
Safety and Tolerability Study of EG-1962 in Aneurysmal Subarachnoid Hemorrhage
Nimodipine Microparticles to Enhance Recovery While Reducing TOxicity After subarachNoid Hemorrhage: Phase I/IIa Multicenter, Controlled, Randomized, Open Label, Dose Escalation, Safety, Tolerability, and Pharmacokinectic Study Comparing EG-1962 and Nimodipine in Patients With Aneurysmal Subarachnoid Hemorrhage
Status: Enrolling
Updated:  1/31/2018
Hackensack University Medical Center
mi
from
Hackensack, NJ
Safety and Tolerability Study of EG-1962 in Aneurysmal Subarachnoid Hemorrhage
Nimodipine Microparticles to Enhance Recovery While Reducing TOxicity After subarachNoid Hemorrhage: Phase I/IIa Multicenter, Controlled, Randomized, Open Label, Dose Escalation, Safety, Tolerability, and Pharmacokinectic Study Comparing EG-1962 and Nimodipine in Patients With Aneurysmal Subarachnoid Hemorrhage
Status: Enrolling
Updated: 1/31/2018
Hackensack University Medical Center
mi
from
Hackensack, NJ
Click here to add this to my saved trials
Safety and Tolerability Study of EG-1962 in Aneurysmal Subarachnoid Hemorrhage
Nimodipine Microparticles to Enhance Recovery While Reducing TOxicity After subarachNoid Hemorrhage: Phase I/IIa Multicenter, Controlled, Randomized, Open Label, Dose Escalation, Safety, Tolerability, and Pharmacokinectic Study Comparing EG-1962 and Nimodipine in Patients With Aneurysmal Subarachnoid Hemorrhage
Status: Enrolling
Updated:  1/31/2018
Overlook Medical Center
mi
from
Summit, NJ
Safety and Tolerability Study of EG-1962 in Aneurysmal Subarachnoid Hemorrhage
Nimodipine Microparticles to Enhance Recovery While Reducing TOxicity After subarachNoid Hemorrhage: Phase I/IIa Multicenter, Controlled, Randomized, Open Label, Dose Escalation, Safety, Tolerability, and Pharmacokinectic Study Comparing EG-1962 and Nimodipine in Patients With Aneurysmal Subarachnoid Hemorrhage
Status: Enrolling
Updated: 1/31/2018
Overlook Medical Center
mi
from
Summit, NJ
Click here to add this to my saved trials
Safety and Tolerability Study of EG-1962 in Aneurysmal Subarachnoid Hemorrhage
Nimodipine Microparticles to Enhance Recovery While Reducing TOxicity After subarachNoid Hemorrhage: Phase I/IIa Multicenter, Controlled, Randomized, Open Label, Dose Escalation, Safety, Tolerability, and Pharmacokinectic Study Comparing EG-1962 and Nimodipine in Patients With Aneurysmal Subarachnoid Hemorrhage
Status: Enrolling
Updated:  1/31/2018
University of New Mexico
mi
from
Albuquerque, NM
Safety and Tolerability Study of EG-1962 in Aneurysmal Subarachnoid Hemorrhage
Nimodipine Microparticles to Enhance Recovery While Reducing TOxicity After subarachNoid Hemorrhage: Phase I/IIa Multicenter, Controlled, Randomized, Open Label, Dose Escalation, Safety, Tolerability, and Pharmacokinectic Study Comparing EG-1962 and Nimodipine in Patients With Aneurysmal Subarachnoid Hemorrhage
Status: Enrolling
Updated: 1/31/2018
University of New Mexico
mi
from
Albuquerque, NM
Click here to add this to my saved trials
Safety and Tolerability Study of EG-1962 in Aneurysmal Subarachnoid Hemorrhage
Nimodipine Microparticles to Enhance Recovery While Reducing TOxicity After subarachNoid Hemorrhage: Phase I/IIa Multicenter, Controlled, Randomized, Open Label, Dose Escalation, Safety, Tolerability, and Pharmacokinectic Study Comparing EG-1962 and Nimodipine in Patients With Aneurysmal Subarachnoid Hemorrhage
Status: Enrolling
Updated:  1/31/2018
Columbia University
mi
from
New York, NY
Safety and Tolerability Study of EG-1962 in Aneurysmal Subarachnoid Hemorrhage
Nimodipine Microparticles to Enhance Recovery While Reducing TOxicity After subarachNoid Hemorrhage: Phase I/IIa Multicenter, Controlled, Randomized, Open Label, Dose Escalation, Safety, Tolerability, and Pharmacokinectic Study Comparing EG-1962 and Nimodipine in Patients With Aneurysmal Subarachnoid Hemorrhage
Status: Enrolling
Updated: 1/31/2018
Columbia University
mi
from
New York, NY
Click here to add this to my saved trials
Safety and Tolerability Study of EG-1962 in Aneurysmal Subarachnoid Hemorrhage
Nimodipine Microparticles to Enhance Recovery While Reducing TOxicity After subarachNoid Hemorrhage: Phase I/IIa Multicenter, Controlled, Randomized, Open Label, Dose Escalation, Safety, Tolerability, and Pharmacokinectic Study Comparing EG-1962 and Nimodipine in Patients With Aneurysmal Subarachnoid Hemorrhage
Status: Enrolling
Updated:  1/31/2018
Lenox Hill Hospital
mi
from
New York, NY
Safety and Tolerability Study of EG-1962 in Aneurysmal Subarachnoid Hemorrhage
Nimodipine Microparticles to Enhance Recovery While Reducing TOxicity After subarachNoid Hemorrhage: Phase I/IIa Multicenter, Controlled, Randomized, Open Label, Dose Escalation, Safety, Tolerability, and Pharmacokinectic Study Comparing EG-1962 and Nimodipine in Patients With Aneurysmal Subarachnoid Hemorrhage
Status: Enrolling
Updated: 1/31/2018
Lenox Hill Hospital
mi
from
New York, NY
Click here to add this to my saved trials
Safety and Tolerability Study of EG-1962 in Aneurysmal Subarachnoid Hemorrhage
Nimodipine Microparticles to Enhance Recovery While Reducing TOxicity After subarachNoid Hemorrhage: Phase I/IIa Multicenter, Controlled, Randomized, Open Label, Dose Escalation, Safety, Tolerability, and Pharmacokinectic Study Comparing EG-1962 and Nimodipine in Patients With Aneurysmal Subarachnoid Hemorrhage
Status: Enrolling
Updated:  1/31/2018
Mount Sinai Hospital
mi
from
New York, NY
Safety and Tolerability Study of EG-1962 in Aneurysmal Subarachnoid Hemorrhage
Nimodipine Microparticles to Enhance Recovery While Reducing TOxicity After subarachNoid Hemorrhage: Phase I/IIa Multicenter, Controlled, Randomized, Open Label, Dose Escalation, Safety, Tolerability, and Pharmacokinectic Study Comparing EG-1962 and Nimodipine in Patients With Aneurysmal Subarachnoid Hemorrhage
Status: Enrolling
Updated: 1/31/2018
Mount Sinai Hospital
mi
from
New York, NY
Click here to add this to my saved trials
Safety and Tolerability Study of EG-1962 in Aneurysmal Subarachnoid Hemorrhage
Nimodipine Microparticles to Enhance Recovery While Reducing TOxicity After subarachNoid Hemorrhage: Phase I/IIa Multicenter, Controlled, Randomized, Open Label, Dose Escalation, Safety, Tolerability, and Pharmacokinectic Study Comparing EG-1962 and Nimodipine in Patients With Aneurysmal Subarachnoid Hemorrhage
Status: Enrolling
Updated:  1/31/2018
Duke Univ Med Ctr
mi
from
Durham, NC
Safety and Tolerability Study of EG-1962 in Aneurysmal Subarachnoid Hemorrhage
Nimodipine Microparticles to Enhance Recovery While Reducing TOxicity After subarachNoid Hemorrhage: Phase I/IIa Multicenter, Controlled, Randomized, Open Label, Dose Escalation, Safety, Tolerability, and Pharmacokinectic Study Comparing EG-1962 and Nimodipine in Patients With Aneurysmal Subarachnoid Hemorrhage
Status: Enrolling
Updated: 1/31/2018
Duke Univ Med Ctr
mi
from
Durham, NC
Click here to add this to my saved trials
Safety and Tolerability Study of EG-1962 in Aneurysmal Subarachnoid Hemorrhage
Nimodipine Microparticles to Enhance Recovery While Reducing TOxicity After subarachNoid Hemorrhage: Phase I/IIa Multicenter, Controlled, Randomized, Open Label, Dose Escalation, Safety, Tolerability, and Pharmacokinectic Study Comparing EG-1962 and Nimodipine in Patients With Aneurysmal Subarachnoid Hemorrhage
Status: Enrolling
Updated:  1/31/2018
Mayfield Clinic
mi
from
Cincinnati, OH
Safety and Tolerability Study of EG-1962 in Aneurysmal Subarachnoid Hemorrhage
Nimodipine Microparticles to Enhance Recovery While Reducing TOxicity After subarachNoid Hemorrhage: Phase I/IIa Multicenter, Controlled, Randomized, Open Label, Dose Escalation, Safety, Tolerability, and Pharmacokinectic Study Comparing EG-1962 and Nimodipine in Patients With Aneurysmal Subarachnoid Hemorrhage
Status: Enrolling
Updated: 1/31/2018
Mayfield Clinic
mi
from
Cincinnati, OH
Click here to add this to my saved trials
Safety and Tolerability Study of EG-1962 in Aneurysmal Subarachnoid Hemorrhage
Nimodipine Microparticles to Enhance Recovery While Reducing TOxicity After subarachNoid Hemorrhage: Phase I/IIa Multicenter, Controlled, Randomized, Open Label, Dose Escalation, Safety, Tolerability, and Pharmacokinectic Study Comparing EG-1962 and Nimodipine in Patients With Aneurysmal Subarachnoid Hemorrhage
Status: Enrolling
Updated:  1/31/2018
Cleveland Clinic Foundation
mi
from
Cleveland, OH
Safety and Tolerability Study of EG-1962 in Aneurysmal Subarachnoid Hemorrhage
Nimodipine Microparticles to Enhance Recovery While Reducing TOxicity After subarachNoid Hemorrhage: Phase I/IIa Multicenter, Controlled, Randomized, Open Label, Dose Escalation, Safety, Tolerability, and Pharmacokinectic Study Comparing EG-1962 and Nimodipine in Patients With Aneurysmal Subarachnoid Hemorrhage
Status: Enrolling
Updated: 1/31/2018
Cleveland Clinic Foundation
mi
from
Cleveland, OH
Click here to add this to my saved trials
Safety and Tolerability Study of EG-1962 in Aneurysmal Subarachnoid Hemorrhage
Nimodipine Microparticles to Enhance Recovery While Reducing TOxicity After subarachNoid Hemorrhage: Phase I/IIa Multicenter, Controlled, Randomized, Open Label, Dose Escalation, Safety, Tolerability, and Pharmacokinectic Study Comparing EG-1962 and Nimodipine in Patients With Aneurysmal Subarachnoid Hemorrhage
Status: Enrolling
Updated:  1/31/2018
Oregon Health and Science University
mi
from
Portland, OR
Safety and Tolerability Study of EG-1962 in Aneurysmal Subarachnoid Hemorrhage
Nimodipine Microparticles to Enhance Recovery While Reducing TOxicity After subarachNoid Hemorrhage: Phase I/IIa Multicenter, Controlled, Randomized, Open Label, Dose Escalation, Safety, Tolerability, and Pharmacokinectic Study Comparing EG-1962 and Nimodipine in Patients With Aneurysmal Subarachnoid Hemorrhage
Status: Enrolling
Updated: 1/31/2018
Oregon Health and Science University
mi
from
Portland, OR
Click here to add this to my saved trials
Safety and Tolerability Study of EG-1962 in Aneurysmal Subarachnoid Hemorrhage
Nimodipine Microparticles to Enhance Recovery While Reducing TOxicity After subarachNoid Hemorrhage: Phase I/IIa Multicenter, Controlled, Randomized, Open Label, Dose Escalation, Safety, Tolerability, and Pharmacokinectic Study Comparing EG-1962 and Nimodipine in Patients With Aneurysmal Subarachnoid Hemorrhage
Status: Enrolling
Updated:  1/31/2018
Medical University of South Carolina
mi
from
Charleston, SC
Safety and Tolerability Study of EG-1962 in Aneurysmal Subarachnoid Hemorrhage
Nimodipine Microparticles to Enhance Recovery While Reducing TOxicity After subarachNoid Hemorrhage: Phase I/IIa Multicenter, Controlled, Randomized, Open Label, Dose Escalation, Safety, Tolerability, and Pharmacokinectic Study Comparing EG-1962 and Nimodipine in Patients With Aneurysmal Subarachnoid Hemorrhage
Status: Enrolling
Updated: 1/31/2018
Medical University of South Carolina
mi
from
Charleston, SC
Click here to add this to my saved trials
Safety and Tolerability Study of EG-1962 in Aneurysmal Subarachnoid Hemorrhage
Nimodipine Microparticles to Enhance Recovery While Reducing TOxicity After subarachNoid Hemorrhage: Phase I/IIa Multicenter, Controlled, Randomized, Open Label, Dose Escalation, Safety, Tolerability, and Pharmacokinectic Study Comparing EG-1962 and Nimodipine in Patients With Aneurysmal Subarachnoid Hemorrhage
Status: Enrolling
Updated:  1/31/2018
Vanderbilt University
mi
from
Nashville, TN
Safety and Tolerability Study of EG-1962 in Aneurysmal Subarachnoid Hemorrhage
Nimodipine Microparticles to Enhance Recovery While Reducing TOxicity After subarachNoid Hemorrhage: Phase I/IIa Multicenter, Controlled, Randomized, Open Label, Dose Escalation, Safety, Tolerability, and Pharmacokinectic Study Comparing EG-1962 and Nimodipine in Patients With Aneurysmal Subarachnoid Hemorrhage
Status: Enrolling
Updated: 1/31/2018
Vanderbilt University
mi
from
Nashville, TN
Click here to add this to my saved trials
Safety and Tolerability Study of EG-1962 in Aneurysmal Subarachnoid Hemorrhage
Nimodipine Microparticles to Enhance Recovery While Reducing TOxicity After subarachNoid Hemorrhage: Phase I/IIa Multicenter, Controlled, Randomized, Open Label, Dose Escalation, Safety, Tolerability, and Pharmacokinectic Study Comparing EG-1962 and Nimodipine in Patients With Aneurysmal Subarachnoid Hemorrhage
Status: Enrolling
Updated:  1/31/2018
University of Calgary/Foothills Medical Centre
mi
from
Calgary,
Safety and Tolerability Study of EG-1962 in Aneurysmal Subarachnoid Hemorrhage
Nimodipine Microparticles to Enhance Recovery While Reducing TOxicity After subarachNoid Hemorrhage: Phase I/IIa Multicenter, Controlled, Randomized, Open Label, Dose Escalation, Safety, Tolerability, and Pharmacokinectic Study Comparing EG-1962 and Nimodipine in Patients With Aneurysmal Subarachnoid Hemorrhage
Status: Enrolling
Updated: 1/31/2018
University of Calgary/Foothills Medical Centre
mi
from
Calgary,
Click here to add this to my saved trials
Study of NNZ-2566 in Patients With Traumatic Brain Injury
A Randomized, Double-Blind, Placebo-Controlled, Dose-Escalation Study of NNZ-2566 in Patients With Traumatic Brain Injury
Status: Enrolling
Updated:  2/1/2018
University of South Alabama
mi
from
Mobile, AL
Study of NNZ-2566 in Patients With Traumatic Brain Injury
A Randomized, Double-Blind, Placebo-Controlled, Dose-Escalation Study of NNZ-2566 in Patients With Traumatic Brain Injury
Status: Enrolling
Updated: 2/1/2018
University of South Alabama
mi
from
Mobile, AL
Click here to add this to my saved trials
Study of NNZ-2566 in Patients With Traumatic Brain Injury
A Randomized, Double-Blind, Placebo-Controlled, Dose-Escalation Study of NNZ-2566 in Patients With Traumatic Brain Injury
Status: Enrolling
Updated:  2/1/2018
Arrowhead Regional Medical Center
mi
from
Colton, CA
Study of NNZ-2566 in Patients With Traumatic Brain Injury
A Randomized, Double-Blind, Placebo-Controlled, Dose-Escalation Study of NNZ-2566 in Patients With Traumatic Brain Injury
Status: Enrolling
Updated: 2/1/2018
Arrowhead Regional Medical Center
mi
from
Colton, CA
Click here to add this to my saved trials
Study of NNZ-2566 in Patients With Traumatic Brain Injury
A Randomized, Double-Blind, Placebo-Controlled, Dose-Escalation Study of NNZ-2566 in Patients With Traumatic Brain Injury
Status: Enrolling
Updated:  2/1/2018
Ronald Reagan UCLA Medical Center
mi
from
Los Angeles, CA
Study of NNZ-2566 in Patients With Traumatic Brain Injury
A Randomized, Double-Blind, Placebo-Controlled, Dose-Escalation Study of NNZ-2566 in Patients With Traumatic Brain Injury
Status: Enrolling
Updated: 2/1/2018
Ronald Reagan UCLA Medical Center
mi
from
Los Angeles, CA
Click here to add this to my saved trials
Study of NNZ-2566 in Patients With Traumatic Brain Injury
A Randomized, Double-Blind, Placebo-Controlled, Dose-Escalation Study of NNZ-2566 in Patients With Traumatic Brain Injury
Status: Enrolling
Updated:  2/1/2018
University of California, Davis Medical Center
mi
from
Sacramento, CA
Study of NNZ-2566 in Patients With Traumatic Brain Injury
A Randomized, Double-Blind, Placebo-Controlled, Dose-Escalation Study of NNZ-2566 in Patients With Traumatic Brain Injury
Status: Enrolling
Updated: 2/1/2018
University of California, Davis Medical Center
mi
from
Sacramento, CA
Click here to add this to my saved trials
Study of NNZ-2566 in Patients With Traumatic Brain Injury
A Randomized, Double-Blind, Placebo-Controlled, Dose-Escalation Study of NNZ-2566 in Patients With Traumatic Brain Injury
Status: Enrolling
Updated:  2/1/2018
University of Miami, Lois Pope Life Center
mi
from
Miami, FL
Study of NNZ-2566 in Patients With Traumatic Brain Injury
A Randomized, Double-Blind, Placebo-Controlled, Dose-Escalation Study of NNZ-2566 in Patients With Traumatic Brain Injury
Status: Enrolling
Updated: 2/1/2018
University of Miami, Lois Pope Life Center
mi
from
Miami, FL
Click here to add this to my saved trials
Study of NNZ-2566 in Patients With Traumatic Brain Injury
A Randomized, Double-Blind, Placebo-Controlled, Dose-Escalation Study of NNZ-2566 in Patients With Traumatic Brain Injury
Status: Enrolling
Updated:  2/1/2018
Queen's Medical Center
mi
from
Honolulu, HI
Study of NNZ-2566 in Patients With Traumatic Brain Injury
A Randomized, Double-Blind, Placebo-Controlled, Dose-Escalation Study of NNZ-2566 in Patients With Traumatic Brain Injury
Status: Enrolling
Updated: 2/1/2018
Queen's Medical Center
mi
from
Honolulu, HI
Click here to add this to my saved trials
Study of NNZ-2566 in Patients With Traumatic Brain Injury
A Randomized, Double-Blind, Placebo-Controlled, Dose-Escalation Study of NNZ-2566 in Patients With Traumatic Brain Injury
Status: Enrolling
Updated:  2/1/2018
Our Lady of the Lake Hospital
mi
from
Baton Rouge, LA
Study of NNZ-2566 in Patients With Traumatic Brain Injury
A Randomized, Double-Blind, Placebo-Controlled, Dose-Escalation Study of NNZ-2566 in Patients With Traumatic Brain Injury
Status: Enrolling
Updated: 2/1/2018
Our Lady of the Lake Hospital
mi
from
Baton Rouge, LA
Click here to add this to my saved trials
Study of NNZ-2566 in Patients With Traumatic Brain Injury
A Randomized, Double-Blind, Placebo-Controlled, Dose-Escalation Study of NNZ-2566 in Patients With Traumatic Brain Injury
Status: Enrolling
Updated:  2/1/2018
Detroit Receiving Hospital and University Health Center
mi
from
Detroit, MI
Study of NNZ-2566 in Patients With Traumatic Brain Injury
A Randomized, Double-Blind, Placebo-Controlled, Dose-Escalation Study of NNZ-2566 in Patients With Traumatic Brain Injury
Status: Enrolling
Updated: 2/1/2018
Detroit Receiving Hospital and University Health Center
mi
from
Detroit, MI
Click here to add this to my saved trials
Study of NNZ-2566 in Patients With Traumatic Brain Injury
A Randomized, Double-Blind, Placebo-Controlled, Dose-Escalation Study of NNZ-2566 in Patients With Traumatic Brain Injury
Status: Enrolling
Updated:  2/1/2018
Sinai-Grace Hospital
mi
from
Detroit, MI
Study of NNZ-2566 in Patients With Traumatic Brain Injury
A Randomized, Double-Blind, Placebo-Controlled, Dose-Escalation Study of NNZ-2566 in Patients With Traumatic Brain Injury
Status: Enrolling
Updated: 2/1/2018
Sinai-Grace Hospital
mi
from
Detroit, MI
Click here to add this to my saved trials
Study of NNZ-2566 in Patients With Traumatic Brain Injury
A Randomized, Double-Blind, Placebo-Controlled, Dose-Escalation Study of NNZ-2566 in Patients With Traumatic Brain Injury
Status: Enrolling
Updated:  2/1/2018
Bronson Methodist Hospital
mi
from
Kalamazoo, MI
Study of NNZ-2566 in Patients With Traumatic Brain Injury
A Randomized, Double-Blind, Placebo-Controlled, Dose-Escalation Study of NNZ-2566 in Patients With Traumatic Brain Injury
Status: Enrolling
Updated: 2/1/2018
Bronson Methodist Hospital
mi
from
Kalamazoo, MI
Click here to add this to my saved trials
Study of NNZ-2566 in Patients With Traumatic Brain Injury
A Randomized, Double-Blind, Placebo-Controlled, Dose-Escalation Study of NNZ-2566 in Patients With Traumatic Brain Injury
Status: Enrolling
Updated:  2/1/2018
University of Cincinnati, Mayfield Clinic
mi
from
Cincinnati, OH
Study of NNZ-2566 in Patients With Traumatic Brain Injury
A Randomized, Double-Blind, Placebo-Controlled, Dose-Escalation Study of NNZ-2566 in Patients With Traumatic Brain Injury
Status: Enrolling
Updated: 2/1/2018
University of Cincinnati, Mayfield Clinic
mi
from
Cincinnati, OH
Click here to add this to my saved trials
Study of NNZ-2566 in Patients With Traumatic Brain Injury
A Randomized, Double-Blind, Placebo-Controlled, Dose-Escalation Study of NNZ-2566 in Patients With Traumatic Brain Injury
Status: Enrolling
Updated:  2/1/2018
Miami Valley Hospital
mi
from
Dayton, OH
Study of NNZ-2566 in Patients With Traumatic Brain Injury
A Randomized, Double-Blind, Placebo-Controlled, Dose-Escalation Study of NNZ-2566 in Patients With Traumatic Brain Injury
Status: Enrolling
Updated: 2/1/2018
Miami Valley Hospital
mi
from
Dayton, OH
Click here to add this to my saved trials
Study of NNZ-2566 in Patients With Traumatic Brain Injury
A Randomized, Double-Blind, Placebo-Controlled, Dose-Escalation Study of NNZ-2566 in Patients With Traumatic Brain Injury
Status: Enrolling
Updated:  2/1/2018
St. Luke's University Hospital
mi
from
Bethlehem, PA
Study of NNZ-2566 in Patients With Traumatic Brain Injury
A Randomized, Double-Blind, Placebo-Controlled, Dose-Escalation Study of NNZ-2566 in Patients With Traumatic Brain Injury
Status: Enrolling
Updated: 2/1/2018
St. Luke's University Hospital
mi
from
Bethlehem, PA
Click here to add this to my saved trials
Study of NNZ-2566 in Patients With Traumatic Brain Injury
A Randomized, Double-Blind, Placebo-Controlled, Dose-Escalation Study of NNZ-2566 in Patients With Traumatic Brain Injury
Status: Enrolling
Updated:  2/1/2018
University of Pittsburgh Medical Center
mi
from
Pittsburgh, PA
Study of NNZ-2566 in Patients With Traumatic Brain Injury
A Randomized, Double-Blind, Placebo-Controlled, Dose-Escalation Study of NNZ-2566 in Patients With Traumatic Brain Injury
Status: Enrolling
Updated: 2/1/2018
University of Pittsburgh Medical Center
mi
from
Pittsburgh, PA
Click here to add this to my saved trials
Study of NNZ-2566 in Patients With Traumatic Brain Injury
A Randomized, Double-Blind, Placebo-Controlled, Dose-Escalation Study of NNZ-2566 in Patients With Traumatic Brain Injury
Status: Enrolling
Updated:  2/1/2018
Texas Health Harris Methodist Hospital Fort Worth
mi
from
Fort Worth, TX
Study of NNZ-2566 in Patients With Traumatic Brain Injury
A Randomized, Double-Blind, Placebo-Controlled, Dose-Escalation Study of NNZ-2566 in Patients With Traumatic Brain Injury
Status: Enrolling
Updated: 2/1/2018
Texas Health Harris Methodist Hospital Fort Worth
mi
from
Fort Worth, TX
Click here to add this to my saved trials
Study of NNZ-2566 in Patients With Traumatic Brain Injury
A Randomized, Double-Blind, Placebo-Controlled, Dose-Escalation Study of NNZ-2566 in Patients With Traumatic Brain Injury
Status: Enrolling
Updated:  2/1/2018
Inova Fairfax Hospital
mi
from
Falls Church, VA
Study of NNZ-2566 in Patients With Traumatic Brain Injury
A Randomized, Double-Blind, Placebo-Controlled, Dose-Escalation Study of NNZ-2566 in Patients With Traumatic Brain Injury
Status: Enrolling
Updated: 2/1/2018
Inova Fairfax Hospital
mi
from
Falls Church, VA
Click here to add this to my saved trials
Study of NNZ-2566 in Patients With Traumatic Brain Injury
A Randomized, Double-Blind, Placebo-Controlled, Dose-Escalation Study of NNZ-2566 in Patients With Traumatic Brain Injury
Status: Enrolling
Updated:  2/1/2018
Charleston Area Medical Center
mi
from
Charleston, WV
Study of NNZ-2566 in Patients With Traumatic Brain Injury
A Randomized, Double-Blind, Placebo-Controlled, Dose-Escalation Study of NNZ-2566 in Patients With Traumatic Brain Injury
Status: Enrolling
Updated: 2/1/2018
Charleston Area Medical Center
mi
from
Charleston, WV
Click here to add this to my saved trials
Study of NNZ-2566 in Patients With Traumatic Brain Injury
A Randomized, Double-Blind, Placebo-Controlled, Dose-Escalation Study of NNZ-2566 in Patients With Traumatic Brain Injury
Status: Enrolling
Updated:  2/1/2018
University of Wisconsin, Froedtert Hospital
mi
from
Milwaukee, WI
Study of NNZ-2566 in Patients With Traumatic Brain Injury
A Randomized, Double-Blind, Placebo-Controlled, Dose-Escalation Study of NNZ-2566 in Patients With Traumatic Brain Injury
Status: Enrolling
Updated: 2/1/2018
University of Wisconsin, Froedtert Hospital
mi
from
Milwaukee, WI
Click here to add this to my saved trials
Study of NNZ-2566 in Patients With Traumatic Brain Injury
A Randomized, Double-Blind, Placebo-Controlled, Dose-Escalation Study of NNZ-2566 in Patients With Traumatic Brain Injury
Status: Enrolling
Updated:  2/1/2018
SUNY Upstate Medical University
mi
from
Syracuse, NY
Study of NNZ-2566 in Patients With Traumatic Brain Injury
A Randomized, Double-Blind, Placebo-Controlled, Dose-Escalation Study of NNZ-2566 in Patients With Traumatic Brain Injury
Status: Enrolling
Updated: 2/1/2018
SUNY Upstate Medical University
mi
from
Syracuse, NY
Click here to add this to my saved trials
Study of NNZ-2566 in Patients With Traumatic Brain Injury
A Randomized, Double-Blind, Placebo-Controlled, Dose-Escalation Study of NNZ-2566 in Patients With Traumatic Brain Injury
Status: Enrolling
Updated:  2/1/2018
University of Arizona
mi
from
Tucson, AZ
Study of NNZ-2566 in Patients With Traumatic Brain Injury
A Randomized, Double-Blind, Placebo-Controlled, Dose-Escalation Study of NNZ-2566 in Patients With Traumatic Brain Injury
Status: Enrolling
Updated: 2/1/2018
University of Arizona
mi
from
Tucson, AZ
Click here to add this to my saved trials
Study of NNZ-2566 in Patients With Traumatic Brain Injury Under EFIC
A Randomized, Double-Blind, Placebo-Controlled, Study of NNZ-2566 in Patients With Traumatic Brain Injury (TBI) Conducted Under an Exception From Informed Consent (EFIC)
Status: Enrolling
Updated:  2/1/2018
Arrowhead Regional Medical Center
mi
from
Colton, CA
Study of NNZ-2566 in Patients With Traumatic Brain Injury Under EFIC
A Randomized, Double-Blind, Placebo-Controlled, Study of NNZ-2566 in Patients With Traumatic Brain Injury (TBI) Conducted Under an Exception From Informed Consent (EFIC)
Status: Enrolling
Updated: 2/1/2018
Arrowhead Regional Medical Center
mi
from
Colton, CA
Click here to add this to my saved trials
Study of NNZ-2566 in Patients With Traumatic Brain Injury Under EFIC
A Randomized, Double-Blind, Placebo-Controlled, Study of NNZ-2566 in Patients With Traumatic Brain Injury (TBI) Conducted Under an Exception From Informed Consent (EFIC)
Status: Enrolling
Updated:  2/1/2018
University of California, Davis Medical Center
mi
from
Sacramento, CA
Study of NNZ-2566 in Patients With Traumatic Brain Injury Under EFIC
A Randomized, Double-Blind, Placebo-Controlled, Study of NNZ-2566 in Patients With Traumatic Brain Injury (TBI) Conducted Under an Exception From Informed Consent (EFIC)
Status: Enrolling
Updated: 2/1/2018
University of California, Davis Medical Center
mi
from
Sacramento, CA
Click here to add this to my saved trials
Study of NNZ-2566 in Patients With Traumatic Brain Injury Under EFIC
A Randomized, Double-Blind, Placebo-Controlled, Study of NNZ-2566 in Patients With Traumatic Brain Injury (TBI) Conducted Under an Exception From Informed Consent (EFIC)
Status: Enrolling
Updated:  2/1/2018
Queen's Medical Center
mi
from
Honolulu, HI
Study of NNZ-2566 in Patients With Traumatic Brain Injury Under EFIC
A Randomized, Double-Blind, Placebo-Controlled, Study of NNZ-2566 in Patients With Traumatic Brain Injury (TBI) Conducted Under an Exception From Informed Consent (EFIC)
Status: Enrolling
Updated: 2/1/2018
Queen's Medical Center
mi
from
Honolulu, HI
Click here to add this to my saved trials
Study of NNZ-2566 in Patients With Traumatic Brain Injury Under EFIC
A Randomized, Double-Blind, Placebo-Controlled, Study of NNZ-2566 in Patients With Traumatic Brain Injury (TBI) Conducted Under an Exception From Informed Consent (EFIC)
Status: Enrolling
Updated:  2/1/2018
Detroit Receiving Hospital and University Health Center
mi
from
Detroit, MI
Study of NNZ-2566 in Patients With Traumatic Brain Injury Under EFIC
A Randomized, Double-Blind, Placebo-Controlled, Study of NNZ-2566 in Patients With Traumatic Brain Injury (TBI) Conducted Under an Exception From Informed Consent (EFIC)
Status: Enrolling
Updated: 2/1/2018
Detroit Receiving Hospital and University Health Center
mi
from
Detroit, MI
Click here to add this to my saved trials
Study of NNZ-2566 in Patients With Traumatic Brain Injury Under EFIC
A Randomized, Double-Blind, Placebo-Controlled, Study of NNZ-2566 in Patients With Traumatic Brain Injury (TBI) Conducted Under an Exception From Informed Consent (EFIC)
Status: Enrolling
Updated:  2/1/2018
Sinai-Grace Hospital
mi
from
Detroit, MI
Study of NNZ-2566 in Patients With Traumatic Brain Injury Under EFIC
A Randomized, Double-Blind, Placebo-Controlled, Study of NNZ-2566 in Patients With Traumatic Brain Injury (TBI) Conducted Under an Exception From Informed Consent (EFIC)
Status: Enrolling
Updated: 2/1/2018
Sinai-Grace Hospital
mi
from
Detroit, MI
Click here to add this to my saved trials
Study of NNZ-2566 in Patients With Traumatic Brain Injury Under EFIC
A Randomized, Double-Blind, Placebo-Controlled, Study of NNZ-2566 in Patients With Traumatic Brain Injury (TBI) Conducted Under an Exception From Informed Consent (EFIC)
Status: Enrolling
Updated:  2/1/2018
University of Pittsburgh Medical Center
mi
from
Pittsburgh, PA
Study of NNZ-2566 in Patients With Traumatic Brain Injury Under EFIC
A Randomized, Double-Blind, Placebo-Controlled, Study of NNZ-2566 in Patients With Traumatic Brain Injury (TBI) Conducted Under an Exception From Informed Consent (EFIC)
Status: Enrolling
Updated: 2/1/2018
University of Pittsburgh Medical Center
mi
from
Pittsburgh, PA
Click here to add this to my saved trials
A Safety and Efficacy Study of NNZ-2566 in Patients With Mild Traumatic Brain Injury (mTBI)
A Randomized, Double-Blind, Placebo-Controlled Study of the Safety and Efficacy of NNZ-2566 in the Acute Treatment of Adolescents and Adults With Mild Traumatic Brain Injury (mTBI)
Status: Enrolling
Updated:  2/1/2018
Fort Bragg
mi
from
Fayetteville, NC
A Safety and Efficacy Study of NNZ-2566 in Patients With Mild Traumatic Brain Injury (mTBI)
A Randomized, Double-Blind, Placebo-Controlled Study of the Safety and Efficacy of NNZ-2566 in the Acute Treatment of Adolescents and Adults With Mild Traumatic Brain Injury (mTBI)
Status: Enrolling
Updated: 2/1/2018
Fort Bragg
mi
from
Fayetteville, NC
Click here to add this to my saved trials
Growth Hormone or Sildenafil as Therapies for Fatigue in Mild- Traumatic-brain-injury (MTBI)
Growth Hormone or Sildenafil as Therapies for Fatigue in MTBI
Status: Enrolling
Updated:  2/1/2018
University of Texas Medical Branch
mi
from
Galveston, TX
Growth Hormone or Sildenafil as Therapies for Fatigue in Mild- Traumatic-brain-injury (MTBI)
Growth Hormone or Sildenafil as Therapies for Fatigue in MTBI
Status: Enrolling
Updated: 2/1/2018
University of Texas Medical Branch
mi
from
Galveston, TX
Click here to add this to my saved trials
Patient-centered Research Into Outcomes Stroke Patients Prefer and Effectiveness Research
Observational Study of Patient-centered Research Into Outcomes Stroke Patients Prefer and Effectiveness Research
Status: Enrolling
Updated:  2/1/2018
Duke Clinical Research Institute
mi
from
Durham, NC
Patient-centered Research Into Outcomes Stroke Patients Prefer and Effectiveness Research
Observational Study of Patient-centered Research Into Outcomes Stroke Patients Prefer and Effectiveness Research
Status: Enrolling
Updated: 2/1/2018
Duke Clinical Research Institute
mi
from
Durham, NC
Click here to add this to my saved trials
Comparative Effectiveness of Rehabilitation Services for Survivors of Acute Ischemic Stroke
Comparative Effectiveness of Rehabilitation Services for Survivors of Acute Ischemic Stroke
Status: Enrolling
Updated:  2/1/2018
Duke Univ Med Ctr
mi
from
Durham, NC
Comparative Effectiveness of Rehabilitation Services for Survivors of Acute Ischemic Stroke
Comparative Effectiveness of Rehabilitation Services for Survivors of Acute Ischemic Stroke
Status: Enrolling
Updated: 2/1/2018
Duke Univ Med Ctr
mi
from
Durham, NC
Click here to add this to my saved trials
Improving Muscle Function in Nutritionally at Risk, Elderly Patients
Phase II, Multi-center, Randomized Control Trial of Beta- Hydroxy-Methyl-Butyrate (HMB) in Improving Physical Muscle Function, in Nutritionally at Risk, Elderly Patients
Status: Enrolling
Updated:  2/1/2018
Wake Forest Baptist Medical Center
mi
from
Winston-Salem, NC
Improving Muscle Function in Nutritionally at Risk, Elderly Patients
Phase II, Multi-center, Randomized Control Trial of Beta- Hydroxy-Methyl-Butyrate (HMB) in Improving Physical Muscle Function, in Nutritionally at Risk, Elderly Patients
Status: Enrolling
Updated: 2/1/2018
Wake Forest Baptist Medical Center
mi
from
Winston-Salem, NC
Click here to add this to my saved trials